PTO/SB/30 (08-00)
Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required

ETRADE! **REQUEST CONTINUED EXAMINATION** (RCE)


Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995. See The American Inventors Protection Act of 1999 (AIPA).

d to respond to a collection of information unless it displays a valid OMB control number.		
Application Number	10/082,905	
Filing Date	February 25, 2002	
First Named Inventor	Saliou	
Group Art Unit	1651	
Examiner Name	Jean C. Witz	
Attorney Docket Number	J&J-2091	

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application. NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which			
established RCE practice.			
1. Submission required under 37 C.F.R. § 1.114			
a. Previously submitted			
i. Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on			
(any unentered amendment(s) referred to above will be entered). ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on			
ii. Consider the arguments in the Appear blief of Nepry blief previously filed on			
iii. 🗍 Other			
b. 🛛 Enclosed			
i. 🛛 Amendment/Reply			
ii. Affidavit(s)/Declaration(s)			
iii. Information Disclosure Statement (IDS)			
iv. Other			
2. Miscellaneous			
a. Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of			
months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required.) b. Other			
3. Fees - The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed			
 a.			
i. RCE fee is required under 37 C.F.R. § 1.17(e)			
ii. Extension of Time (37 C.F.R. §§ 1.136 and 1.17)			
iii. Other			
b. Check in the amount of \$ enclosed			
c. Payment by credit card (Form PTO-2038 enclosed)			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED			
Name (print/type) William P. McGowan	Registration No.	39,301	
Signature	Date	April 16, 2004	
CERTIFICATE OF MAILING OR TRANSMISSION			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class			
mail in an envelope addressed to: Mail Stop RCE, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or			
facsimile transmitted to the U.S. Patent and Trademark Office on: April 16, 2004			
Name (print/type) William E. MeGowan			
Signature	Date	April 16, 2004	

04/20/2004 JEALIHAN 00000032 100750 10082905

01 FC:1801





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Claude Saliou et al.

Serial No.

10/082,905

Filed

February 25, 2002

Title

USE OF LEGUME PRODUCTS FOR TREATMENT OF EXTERNAL

AGGRESSIONS

Art Unit

1651

Examiner

Jean C. Witz

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231 on

April 16, 2004 (Date of Deposit)

William E. McGowan

(Name of applicant, assignee, or Registered Representative)

(Signature)

April 16, 2004

(Date of Signature)

Commissioner of Patents PO Box 1450 Alexandria, VA 22313

AMENDMENT

Dear Sir:

In response to the Office Action of December 16, 2003, please amend the aboveidentified application as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.